These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 17718660)

  • 21. Generic products of antiepileptic drugs (AEDs): is it an issue?
    Bialer M
    Epilepsia; 2007 Oct; 48(10):1825-32. PubMed ID: 17850324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
    Kwong WJ; Kamat S; Fang C
    Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy.
    Das S; Jiang X; Jiang W; Ting TY; Polli JE
    Epilepsy Behav; 2020 Apr; 105():106936. PubMed ID: 32092462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.
    Kelton CM; Chang LV; Guo JJ; Yu Y; Berry EA; Bian B; Heaton PC
    Appl Health Econ Health Policy; 2014 Apr; 12(2):165-77. PubMed ID: 24550087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generic antiepileptic drugs and associated medical resource utilization in the United States.
    Labiner DM; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Helmers SL
    Neurology; 2010 May; 74(20):1566-74. PubMed ID: 20393142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy.
    Markowitz MA; Mauskopf JA; Halpern MT
    Neurology; 1998 Oct; 51(4):1026-33. PubMed ID: 9781524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
    Murry L; Gerleman B; Urick B; Urmie J
    J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
    Layton S; Barbeau M
    Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiepileptic drugs: generic versus branded treatments.
    Heaney DC; Sander JW
    Lancet Neurol; 2007 May; 6(5):465-8. PubMed ID: 17434101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom.
    Verdian L; Yi Y
    Seizure; 2010 Jan; 19(1):1-11. PubMed ID: 19942457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.
    Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G
    Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
    Zachry WM; Doan QD; Clewell JD; Smith BJ
    Epilepsia; 2009 Mar; 50(3):493-500. PubMed ID: 18616554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany--a nationwide population-based study in children and adults.
    Hamer HM; Dodel R; Strzelczyk A; Balzer-Geldsetzer M; Reese JP; Schöffski O; Graf W; Schwab S; Knake S; Oertel WH; Rosenow F; Kostev K
    J Neurol; 2012 Nov; 259(11):2376-84. PubMed ID: 22544296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescribing generic antiepileptic drugs: Issues and concerns for nurse practitioners.
    Barrett MW
    J Am Acad Nurse Pract; 2010 Jun; 22(6):300-4. PubMed ID: 20536627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prescription drug costs and the generic dispensing ratio.
    Liberman JN; Roebuck MC
    J Manag Care Pharm; 2010 Sep; 16(7):502-6. PubMed ID: 20726679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of lamotrigine and other antiepileptic drugs in paediatric patients at a Malaysian hospital.
    Ab Rahman AF; Ibrahim MI; Ismail HI; Seng TB
    Pharm World Sci; 2005 Oct; 27(5):403-6. PubMed ID: 16341748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of copayments and generic substitution on the use and costs of prescription drugs.
    Smith DG
    Inquiry; 1993; 30(2):189-98. PubMed ID: 8314607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy.
    Haskins LS; Tomaszewski KJ; Crawford P
    Epilepsy Behav; 2005 Aug; 7(1):98-105. PubMed ID: 15961350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of add-on lamotrigine therapy in clinical practice.
    Knoester PD; Boendermaker AJ; Egberts AC; Hekster YA; Keyser A; Severens JL; Renier WO; Deckers CL
    Epilepsy Res; 2005 Dec; 67(3):143-51. PubMed ID: 16288850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generic substitution for brand name antiepileptic drugs: a survey.
    Guberman A; Corman C
    Can J Neurol Sci; 2000 Feb; 27(1):37-43. PubMed ID: 10676586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.